Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT ORLOWSKI and YAGO NIETO.
ROBERT ORLOWSKI
Connection Strength
2.249
YAGO NIETO
  1. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.191
  2. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.
    View in: PubMed
    Score: 0.149
  3. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 Oct 31; 14(1):189.
    View in: PubMed
    Score: 0.062
  4. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma with Deletion 17p. Transplant Cell Ther. 2024 Oct 22.
    View in: PubMed
    Score: 0.062
  5. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther. 2024 Aug; 30(8):772.e1-772.e11.
    View in: PubMed
    Score: 0.061
  6. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 May 17; 14(1):82.
    View in: PubMed
    Score: 0.060
  7. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 May; 204(5):1944-1952.
    View in: PubMed
    Score: 0.060
  8. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.
    View in: PubMed
    Score: 0.059
  9. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672.
    View in: PubMed
    Score: 0.059
  10. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.
    View in: PubMed
    Score: 0.058
  11. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.
    View in: PubMed
    Score: 0.057
  12. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.
    View in: PubMed
    Score: 0.057
  13. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.
    View in: PubMed
    Score: 0.056
  14. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.
    View in: PubMed
    Score: 0.056
  15. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.
    View in: PubMed
    Score: 0.055
  16. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.
    View in: PubMed
    Score: 0.053
  17. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
    View in: PubMed
    Score: 0.053
  18. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.
    View in: PubMed
    Score: 0.053
  19. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214.
    View in: PubMed
    Score: 0.051
  20. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.
    View in: PubMed
    Score: 0.051
  21. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457.
    View in: PubMed
    Score: 0.050
  22. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120.
    View in: PubMed
    Score: 0.048
  23. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837.
    View in: PubMed
    Score: 0.047
  24. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238.
    View in: PubMed
    Score: 0.045
  25. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.045
  26. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.
    View in: PubMed
    Score: 0.044
  27. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.
    View in: PubMed
    Score: 0.044
  28. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.
    View in: PubMed
    Score: 0.043
  29. Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.
    View in: PubMed
    Score: 0.043
  30. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
    View in: PubMed
    Score: 0.042
  31. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74.
    View in: PubMed
    Score: 0.042
  32. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093.
    View in: PubMed
    Score: 0.041
  33. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.
    View in: PubMed
    Score: 0.041
  34. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.
    View in: PubMed
    Score: 0.040
  35. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.037
  36. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.037
  37. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268.
    View in: PubMed
    Score: 0.036
  38. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.
    View in: PubMed
    Score: 0.036
  39. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93.
    View in: PubMed
    Score: 0.033
  40. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.
    View in: PubMed
    Score: 0.032
  41. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8.
    View in: PubMed
    Score: 0.032
  42. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.